PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
9.56%
Some net income increase while AVGO is negative at -432.89%. John Neff would see a short-term edge over the struggling competitor.
-2.81%
Negative yoy D&A while AVGO is 326.23%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-345.83%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
5.56%
Less SBC growth vs. AVGO's 247.37%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
101.29%
Less working capital growth vs. AVGO's 469.95%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
24.00%
AR growth while AVGO is negative at -212.20%. John Neff would note competitor possibly improving working capital while we allow AR to rise.
37.72%
Inventory shrinking or stable vs. AVGO's 2505.88%, indicating lean supply management. David Dodd would confirm no demand shortfall.
137.50%
A yoy AP increase while AVGO is negative at -119.12%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
177.03%
Growth well above AVGO's 210.94%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-60.32%
Negative yoy while AVGO is 642.86%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
63.71%
Operating cash flow growth above 1.5x AVGO's 31.22%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-27.42%
Both yoy lines negative, with AVGO at -12.86%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
-396.50%
Both yoy lines negative, with AVGO at -5700.00%. Martin Whitman would suspect an environment with fewer attractive securities or a strategic pivot to internal growth.
34.44%
Liquidation growth of 34.44% while AVGO is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-4966.67%
Both yoy lines negative, with AVGO at -125.45%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-88.66%
Both yoy lines negative, with AVGO at -11908.24%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
183.82%
Stock issuance far above AVGO's 48.61%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
16.35%
Buyback growth of 16.35% while AVGO is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.